Company Overview - Hongbo Pharmaceutical, established on December 14, 2007, is located at 59 Kaiqing Road, Pudong New District, Shanghai. The company was listed on November 1, 2022. Its main business involves drug discovery, pharmaceutical process research and development, and commercial production of raw material intermediates [1]. Business Revenue Composition - The revenue composition of Hongbo Pharmaceutical is as follows: drug discovery accounts for 52.67%, commercial production for 35.00%, process research and development for 8.10%, and other supplementary activities for 4.23% [1]. Stock Performance - On September 9, Hongbo Pharmaceutical's stock fell by 5.02%, closing at 36.33 CNY per share, with a trading volume of 213 million CNY and a turnover rate of 7.45%. The total market capitalization is 5.071 billion CNY [1]. Major Shareholders - Among the top ten circulating shareholders of Hongbo Pharmaceutical, a fund under China Europe Fund ranks as a significant holder. The China Europe Science and Technology Innovation Theme Mixed Fund (LOF) A (501081) entered the top ten shareholders in the second quarter, holding 1.1669 million shares, which is 1.52% of the circulating shares. The estimated floating loss today is approximately 2.2404 million CNY [2]. Fund Performance - The China Europe Science and Technology Innovation Theme Mixed Fund (LOF) A (501081) was established on June 28, 2019, with a latest scale of 2.238 billion CNY. Year-to-date returns are 51.39%, ranking 521 out of 8179 in its category. Over the past year, returns are 125.21%, ranking 140 out of 7984, and since inception, returns are 171.27% [2]. Fund Management - The fund manager of the China Europe Science and Technology Innovation Theme Mixed Fund (LOF) A (501081) is Jiejie Shao. As of the report date, Shao has been in the position for 5 years and 210 days, managing a total fund asset size of 9.284 billion CNY. The best fund return during the tenure is 114.56%, while the worst return is 0.58% [3].
泓博医药股价跌5.02%，中欧基金旗下1只基金位居十大流通股东，持有116.69万股浮亏损失224.04万元